FDA inspection operations face risk of further disruption amid mass HHS layoffs: report
While the FDA’s inspection figures for drug manufacturing facilities have yet to fully recover from the COVID-19 pandemic, sweeping staff cuts from the Department of Health and Human Services (HHS) could exacerbate the problem even further, CBS News reports.
While the FDA’s inspection figures for drug manufacturing facilities have yet to fully recover from the COVID-19 pandemic, sweeping staff cuts from the Department of Health and Human Services (HHS) could exacerbate the problem even further, CBS News reports.
